Novartis AG (NVS)
After hours:
| Previous Close | 81.86 |
| Open | 83.52 |
| Bid | 84.28 x 900 |
| Ask | 84.85 x 800 |
| Day's Range | 83.36 - 84.83 |
| 52 Week Range | 79.09 - 95.17 |
| Volume | |
| Avg. Volume | 2,452,129 |
| Market Cap | 189.145B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 7.91 |
| EPS (TTM) | 10.73 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (4.10%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | 104.40 |
- Zacks
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
- GlobeNewswire
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower d
- Zacks
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
